Main Use | Active Ingredient | Marketed Name |
Renal cell carcinoma or soft tissue sarcoma | Pazopanib | Votrient |
Uses
Votrient (Pazopanib) is used to treat patients with:
Dosage and Administration
Votrient is usually prescribed at a starting dosage of 800 mg per daily. The tablets are taken orally and should be taken on an empty stomach (one hour before or two hours after a meal).
In patients with renal cell carcinoma, after a loading dose, the dosage can be reduced by 400mg, and then decreased or increased in 200mg increments depending on individual response.
In soft tissue sarcoma, after a loading dose a decrease or increase in 200mg increments can be implemented depending on individual treatment response.
Patients with hepatic impairment may require different dosages.
Side effects
Signs of an allergic reaction including hives, difficult breathing, or swelling of the face, lips, tongue, or throat will require urgent medical attention.
More serious side effects of Votrient include:
If you notice any of the above side effects, contact your doctor as soon as possible.
Less severe side effects you may notice can include:
Precautions
Fatal hepatotoxicity has been observed in clinical trials. Blood tests to monitor hepatic function should be scheduled regularly.
Pazopanib is not recommended during pregnancy as there is a chance of it harming the unborn baby. It is uncertain if Pazopanib is passed through breastmilk.
Tell your doctor of all medicines you are currently taking, especially any blood thinners as Votrient can interfere with wound healing.